Now more than ever, it is undeniable how integral science and research have become to public health. Nationwide, doctors, scientists and experts are working around the clock to find the most up-to-date and reliable information to prevent and stop the spread of Covid-19.
Here are five must-know women who are shattering ceilings, making groundbreaking discoveries, and spreading public awareness during the global pandemic.
Joy Buolamwini is the founder of the Algorithmic Justice League (AJL), a computer scientist and an expert in artificial intelligence bias. Four years ago, when Buolamwini was a graduate student at MIT’s Media Lab, she began looking into the racial and gender disparities in commercially-available facial recognition technologies. Her research culminated in two groundbreaking, peer-reviewed studies, published in 2018 and 2019, that revealed
New Delhi: Harvey Alter and Charles Rice from the US, and Michael Houghton from the UK won the Nobel Prize in Medicine for discovering the hepatitis C virus.
The 2020 Nobel Prize in Chemistry was shared, for the first time, by two women — French microbiologist, geneticist, and biochemist Emmanuelle Charpentier and American biochemist Jennifer A. Doudna, for inventing a genetic ‘scissors’ that allows scientists to ‘cut and paste’ inside a genome sequence.
In episode 588 of ‘Cut the Clutter’, ThePrint’s Editor-in-Chief Shekhar Gupta decodes the science behind the two wins.
Hepatitis C virus discovery
Harvey Alter, the chief infectious diseases investigator at National Institute of Health in the US, did a lot of his early work at a big blood banking system in Bethesda, Maryland on the outskirts of Washington, DC in the 1970s.
Michael Houghton is head of Li Ka Shing Virology Institute
Over the past decade, we witnessed unprecedented advances in the field of biogerontology, and the massive convergence of biotechnology, information technology, AI, and medicine. And now we are witnessing the birth of a new field of longevity medicine, which integrates the latest advances in many of these fields of science and technology. My definition longevity medicine is advanced personalized preventative medicine powered by deep biomarkers of aging and longevity.
And, like in the field of AI for drug discovery, women are at the forefront of this revolution and there were precedents when we had to look for a male physician to make a conference panel more diverse.
One of the physician-scientists who stands out in this area is Dr. Evelyne Yehudit Bischof. I first got a note with a request for more information on one of
European Stocks Decline on Trump Virus Woes as M&A Stocks Gain
(Bloomberg) — European equities retreated after President Donald Trump tested positive for the coronavirus, fueling uncertainty a month before the U.S. election.The Stoxx 600 index was down 0.6% at 10:49 a.m. in London, paring a drop of as much as 1.2%. While retail, oil and travel stocks led the declines, construction and media shares advanced. Still, European losses were muted compared with U.S. futures where S&P 500 e-mini futures tumbled 1.6%.Trump announced early Friday that he and First Lady Melania Trump had tested positive for Covid-19, shortly after one of his closest aides, Hope Hicks, had fallen ill with the coronavirus. The news fueled concerns among market players about the outcome of the U.S. election and Trump’s ability to campaign and govern.“With some key state polls tight and this positive test coming so close to the election, this
Wednesday, September 30, 2020 – Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Live Leveraging Intelligent Tech for Drug Development Forum on September 30, 2020.
AI, automation and data integration are condensing the timeline from discovery to development and solving biological problems. On September 30th, leaders from biotech and pharma will discuss specific examples of how these technological advancements are reshaping the drug development landscape.
While technology continues to revolutionize biotech, pharmaceutical companies are investing heavily in modernizing internally to embrace and embed these innovations throughout their organizational structure and culture. On the clinical trial front, not only are sponsors pressed to have remote and decentralized designs for their trial models due to the ongoing
Helium balloons are a quintessential party favor, a fixture of any birthday, wedding or anniversary party. But few consumers seem to know that helium is a limited resource — and one which physics experiments and medical imaging tools rely on to work. Worse, once a helium balloon pops, that gas is lost forever — it floats upwards and escapes into space, never to be seen on Earth again.
Now, with the specter of a recent helium shortage still looming, consumers are being asked to ration their helium in order to save science and medicine. The idea that party supply companies and consumers can’t give up helium balloons in order to save these more worthy enterprises might seem a tad selfish; but this is how the market thinks. Yet a few inventors around the country have a brilliant compromise: what if we could make a “balloon” that needed no helium gas
“It is more important to know what kind of patient the disease has than to know what kind of disease the patient has.”
Although Hippocrates made this keen observation more than 2,400 years ago, physicians did not have the tools to decipher the biological and environmental factors influencing an individual’s health and well-being until recently.
Since the human genome was finally mapped in 2003, scientists have made tremendous progress in advancing personalized medicine. By tailoring health care to an individual’s biological characteristics, circumstances, and values, personalized medicine can bring unprecedented benefits to patients with rare genetic disorders, cancer, and other diseases.
The widely variable effects of the novel coronavirus serve as a painful reminder of the importance of understanding how and why people respond differently to the same disease.
But two recent moves by the Trump administration threaten to turn back the clock on biomedical progress in personalized
Singapore, 22 September 2020 – Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRF’s initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.
SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.
“Singapore’s well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing